EV-201: Enfortumab Vedotin in Advanced Urothelial Cancer Previously Treated With Platinum Chemotherapy and Immune Checkpoint Inhibitors

May 31 - June 4, 2019; Chicago, Illinois
EV-201 data showed a response rate of 44% with enfortumab vedotin in patients with advanced urothelial cancer who progressed after platinum chemotherapy and checkpoint inhibitors.
Format: Microsoft PowerPoint (.ppt)
File Size: 249 KB
Released: June 7, 2019


Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Astellas and Seattle Genetics, Inc.
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD person default Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS person default Arlene O. Siefker-Radtke, MD Released: July 19, 2021

Ignacio Duran, MD, PhD, provides his thoughts on the latest clinical strategies on targeting FGFR in bladder cancer and beyond in this online educational activity from Clinical Care Options (CCO).

Ignacio Duran, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: June 14, 2021 Expired: June 13, 2022

Downloadable slideset reviewing the latest data on on FGFR signaling in bladder cancer and beyond, from Clinical Care Options (CCO)

Ignacio Duran, MD, PhD Released: June 14, 2021

Gain key clinical insights quickly with this short slideset from CCO on the latest data on FGFR signaling in bladder cancer and beyond.

Ignacio Duran, MD, PhD Released: June 14, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.